CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myeloma.
B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
本研究评估复发/难治性多发性骨髓瘤患者在接受塔奎妥单抗后序贯使用B细胞成熟抗原（BCMA）靶向疗法的结局。10例患者的中位随访时间为9.5个月，中位无进展生存期为5.5个月。初步结果提示，这一治疗序贯策略可行。
Talquetamab recently received approval for relapsed refractory multiple myeloma.
However, there is currently no available data on how patients perform with BCMA based agents after progression on talquetamab.
Herein, we present the outcome of 10 patients who received BCMA based therapies following talquetamab. The median follow-up was 9. 5 months (range: 6-24 months). The median progression free survival was 5. 5 months (range: 1-10 months). Patients had varying grades of cytokine release syndrome and Immune effector cell-associated neurotoxicity syndrome.
Our results suggest that treatment with talquetamab followed by BCMA based therapies is feasible and can be considered as clinically indicated.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
